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Persistent antigen stimulation in chronic infections has been associated with
antigen-specific T cell dysfunction and upregulation of inhibitory receptors, including
programmed cell death protein 1 (PD-1). Pulmonary tuberculosis (TB) disease is
characterized by high levels of Mycobacterium tuberculosis (Mtb), yet the relationship
between bacterial load, PD-1 expression, and Mtb-specific T cell function in human TB
has not been well-defined. Using peripheral blood samples from adults with LTBI and
with pulmonary TB disease, we tested the hypothesis that PD-1 expression is associated
with bacterial load and functional capacity of Mtb-specific T cell responses.We found that
PD-1 was expressed at significantly higher levels on Th1 cytokine-producingMtb-specific
CD4T cells from patients with smear-positive TB, compared with smear-negative TB and
LTBI, which decreased after completion of anti-TB treatment. By contrast, expression of
PD-1 on Mtb-specific CD8T cells was significantly lower than on Mtb-specific CD4T
cells and did not differ by Mtb infection and disease status. In vitro stimulation of PBMC
with Mtb antigens demonstrated that PD-1 is induced on proliferating Mtb-specific CD4T
cells and that Th1 cytokine production capacity is preferentially maintained within PD-1+
proliferating CD4T cells, compared with proliferating Mtb-specific CD4T cells that lack
PD-1 expression. Together, these data indicate that expression of PD-1 on Mtb-specific
CD4T cells is indicative of mycobacterial antigen exposure and identifies a population
of effector cells with Th1 cytokine production capacity. These studies provide novel
insights into the role of the PD-1 pathway in regulating CD4 and CD8T cell responses
in Mtb infection and provide rationale for future studies to evaluate PD-1 expression on
antigen-specific CD4T cells as a potential biomarker for bacterial load and treatment
response in human TB.
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INTRODUCTION
Infection with Mycobacterium tuberculosis (Mtb) is responsible
for over 10 million cases of tuberculosis (TB) and approximately
1.7 million deaths each year (1). The number of people who
develop active TB disease represents a minority of the estimated
1.7 billion people infected with Mtb who remain asymptomatic
and are considered to have latent Mtb infection (LTBI) (2).
Infection with Mtb is increasingly recognized to represent a
spectrum ranging from eradication of the bacteria, establishment
of LTBI, sub-clinical disease, and active TB disease (3). However,
the immune correlates of these diverse states of Mtb infection
remain poorly understood.
CD4T cells play an important role in immune containment
of Mtb infection. Mtb-infected mice that lack CD4T cells
demonstrate increased susceptibility to TB (4–6), and
reactivation of TB is increased following CD4T cell depletion
in macaques with LTBI (7, 8). Moreover, people with LTBI who
are co-infected with human immunodeficiency virus (HIV) are
at substantially higher risk of developing active TB compared
with HIV-uninfected individuals (1, 9–11). In addition to CD4T
cells, CD8 T cells play an important role in containing Mtb
infection by release of cytokines and production of cytotoxic
molecules such as perforin, granzymes, and granulysin (12–19).
Increasing evidence indicates Mtb-specific CD4 and CD8T cells
develop progressive dysfunction in people who develop active TB
disease, including decreased IL-2 production (20–23), impaired
proliferative capacity (20, 24), and diminished cytolytic activity
(25, 26).
Although there is mounting evidence of progressive T cell
dysfunction with increasing bacterial load, the mechanisms
leading to functional impairment of Mtb-specific T cell responses
in people with active TB disease have not been well-defined.
One mechanism leading to inhibition of antigen-specific T cell
effector function is expression of inhibitory receptors, such as
PD-1, CTLA-4, LAG-3, TIM-3, and BTLA, which negatively
regulate activated T cells (27). Progressive dysfunction of
antigen-specific T cells in tumors and several models of chronic
viral infections, including lymphocytic choriomeningitis virus
(LCMV), HIV, hepatitis C virus (HCV), and hepatitis B virus
(HBV), has been linked to sustained high expression of inhibitory
receptors (27, 28). Importantly, antibody-mediated blockade
of inhibitory receptor signaling pathways has been shown to
enhance antigen-specific T cell function and promote control
of infectious pathogens (29), and forms the basis of checkpoint
blockade immunotherapy in the treatment of several different
cancers (30).
Despite intensive investigation of inhibitory receptor
expression by T cells in the settings of tumors and chronic
viral infections, expression of inhibitory receptors has been less
well-characterized in Mtb infection and TB disease. Pulmonary
TB disease in humans is associated with high bacterial loads in
the lung, with smear-positive pulmonary TB patients harboring
∼10,000 to>108 bacilli per ml of sputum (31, 32). In non-human
primates, PD-1 expression is upregulated in tissues of rhesus
monkeys with severe TB disease (33). Mtb infection of PD-1−/−
mice leads to increased frequencies of Mtb-specific CD4T
cells; however, PD-1−/− mice display enhanced susceptibility
to TB disease, characterized by increased bacterial loads,
increased inflammatory and necrotic responses in the lungs,
and reduced survival (34–36). These studies in PD-1-deficient
mice demonstrate a necessary role for PD-1 in limiting excessive
IFN-γ production by CD4T cells, which has been associated
with exacerbated disease in murine models of TB (37).
Increasing evidence suggests PD-1 expression is upregulated
on innate and adaptive immune cells in the setting of Mtb
infection and disease in humans. Expression of PD-1 and
its ligands, PD-L1, and PD-L2, has also been reported to be
increased on NK cells (38), neutrophils (39), and monocytes
(40, 41) from patients with active TB disease. PD-1 has also been
reported to be expressed at higher levels on Mtb-specific CD4T
cells in individuals with LTBI, compared to Mtb-uninfected
individuals who have been vaccinated with Bacillus Calmette-
Guérin (BCG) (42). However, the relationship between bacterial
load, PD-1 expression and functional capacity of Mtb-specific
T cells in humans remains incompletely understood. To test
the hypothesis that PD-1 expression is associated with bacterial
load and Mtb-specific T cell functional capacity, we conducted a
comprehensive analysis of PD-1 expression on Mtb-specific CD4
and CD8T cells in clinically well-characterized cohorts of South
African adults across a spectrum of Mtb infection and disease.
MATERIALS AND METHODS
Study Population and Sample Collection
Participants between the ages of 18–65 years were recruited in
the Western Cape province of South Africa; all participants were
seronegative for HIV-1 antibodies. Healthy, asymptomatic adults
with latent Mtb infection (LTBI) were identified as individuals
with no previous history of diagnosis or treatment for TB disease,
and with an IFN-γ+ T cell response to CFP-10 and/or ESAT-
6 antigens by a QuantiFERON R©-TB Gold In-Tube assay, or
an 8h whole blood intracellular cytokine staining assay (20).
Patients with pulmonary TB were diagnosed by standard sputum
smear microscopy and/or sputum culture and classified into
two groups: sputum smear-negative (smear−) and smear-positive
(smear+). All sputum smear− TB patients had sputum cultures
that were positive for Mtb growth. Blood was collected from
patients with TB either prior to, or within the first 7 days of
starting the standard 6-month course of TB treatment. A subset
of TB patients was followed longitudinally on TB treatment,
with additional blood samples collected 2 and 6 months after
initiating treatment. All TB patients included in the study had
been newly diagnosed with TB and reported no previous history
of diagnosis or treatment for TB disease. Blood was collected in
BD Vacutainer R© tubes containing sodium heparin. PBMC were
isolated by density centrifugation and frozen in liquid nitrogen
until further use.
Ethics Statement
This study was conducted in accordance with the principles
expressed in the Declaration of Helsinki. All participants gave
written informed consent for the study, which was approved
by the institutional review boards at the University of Cape
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Town, Stellenbosch University, and Emory University; and by the
Western Cape Province Department of Health.
Antigens
The following antigens were used in this study: pools of 15-mer
overlapping peptides spanning the full length sequences of CFP-
10, ESAT-6, TB10.4, and human cytomegalovirus (HCMV) pp65,
pooled by protein (1.25 µg/ml/peptide in whole blood and BAL
intracellular cytokine staining assays; 0.1 µg/ml/peptide in 6-
day proliferation assays); Mtb purified protein derivative (PPD;
10µg/ml in whole blood and BAL ICS assays; 1µg/ml in 6-
day proliferation assay; Statens Serum Institut, Denmark); and
staphylococcal enterotoxin B (SEB; Sigma-Aldrich) as a positive
control (1µg/ml in whole blood and BAL ICS assays; 0.1µg/ml
in 6-day proliferation assay). The HCMV pp65 peptide pool was
obtained through the NIH AIDS Reagent Program, Division of
AIDS, NIAID, NIH (43–45).
Antibodies
The following human monoclonal fluorescently-conjugated
antibodies were used in this study: anti-CD3 Pacific Blue (clone
UCHT1), anti-CD3 APC-H7 (clone SK7), anti-CD4 APC (clone
RPA-T4), anti-CD8 PerCP-Cy5.5 (clone SK-1), anti-IFN-γ Alexa
Fluor 700 (clone B27), anti-IL-2 FITC (clone 5344.111), anti-IL-
2 APC (clone MQ1-17H12), anti-CCR7 FITC (clone 150503),
anti-CD45RA PE-Cy7 (clone HI100), all from BD Biosciences,
and anti-CD4 QDot605 (clone S3.5; Life Technologies), anti-
TNF-α PE-Cy7 (clone Mab11; eBiosciences), and anti-PD-1
PE (clone EH12.2H7; BioLegend). For PD-1/PD-L1 blockade
experiments, LEAFTM purified anti-human PD-L1 Ab (clone
29E.2A3) and LEAFTM purified IgG2b isotype-matched control
Ab (clone MPC-11) were obtained from BioLegend.
Whole Blood Intracellular Cytokine
Staining (ICS) Phenotyping Assay
Whole blood ICS assays were performed as previously described
(20). Briefly, immediately after collection, whole blood was
incubated with antigens (described above); blood incubated with
no antigen served as a negative control. Brefeldin A (10µg/ml;
Sigma-Aldrich) was added after 3 h incubation at 37◦C, and the
incubation continued for an additional 5 h. Blood was diluted in
FACS Lysing Solution (BD Biosciences) to lyse red blood cells
and fix white blood cells, which were cryopreserved in freezing
medium containing 50% RPMI, 40% fetal calf serum (FCS), and
10% dimethyl sulfoxide (DMSO; Sigma-Aldrich), and stored in
liquid nitrogen until use.
Cryopreserved, fixed white blood cells were thawed and
washed in PBS, followed by a wash with Perm/Wash Buffer
(BD Biosciences). For analysis of PD-1 expression and cytokine
production profiles, cells were stained for 1 h at 4◦C with the
following Abs: anti-CD3 Pacific Blue, anti-CD4 QDot605, anti-
CD8 PerCP-Cy5.5, anti-IFN-γ Alexa Fluor 700, anti-IL-2 FITC,
anti-TNF-α PE-Cy7, and anti-PD-1 PE. For analysis of PD-1
expression andmemory T cell phenotypes, cells were stained with
anti-CCR7 FITC for 20min at 37◦C, washed with Perm/Wash
Buffer, and then stained for 1 h at 4◦C with the following Abs:
anti-CD3 Pacific Blue, anti-CD4 QDot605, anti-CD8 PerCP-
Cy5.5, anti-CD45RA PE-Cy7, anti-PD-1 PE, and anti-IFN-γ
Alexa Fluor 700. Cells were then washed in Perm/Wash Buffer
and acquired on a BD LSRII flow cytometer.
Bronchoalveolar Lavage (BAL) Sample
Processing
Bronchoscopy was performed on individuals with LTBI
according to routine clinical care guidelines and routine
bronchoscopy standard operating procedures (46). A flexible
standard diagnostic bronchoscopy was conducted under local
anesthesia with lidocaine as per British Thoracic Society
guidelines. BAL was performed with 160ml sterile saline
installed in aliquots and recovered into a sterile collection bottle.
BAL fluid was kept on ice and transported to the laboratory for
further processing. BAL fluid was filtered through a 100µm
filter; mononuclear cells were isolated by centrifugation, washed
in sterile PBS, and suspended in RPMI containing 10% human
male AB serum. BAL mononuclear cells were stimulated under
the following conditions: media alone (negative control), a
combined CFP-10/ESAT-6 peptide pool, PPD, and SEB. Cells
were incubated for 1 h at 37◦C, after which Brefeldin Awas added
(10µg/ml) and the cells were incubated at 37◦C for an additional
5 h. Cells were washed in PBS, stained with LIVE/DEAD Fixable
Violet Dead Cell Stain (Vivid; Life Technologies), washed again
in PBS, and fixed using FACS Lysing Solution. Cells were washed
in PBS and then permeabilized using Perm/Wash Buffer and
stained for 1 h at 4◦C with the following antibodies: anti-CD3
APC-H7, anti-CD4 APC, anti-CD8 PerCP-Cy5.5, anti-IFN-γ
Alexa Fluor 700, anti-IL-2 FITC, anti-TNF-α PE-Cy7, and
anti-PD-1 PE. Cells were then washed with Perm/Wash Buffer,
suspended in PBS, and acquired on a BD LSRII flow cytometer.
Proliferation Assays and in vitro
PD-1/PD-L1 Blockade
Six-day proliferation assays were performed using freshly isolated
PBMC labeled with 0.5µg/ml CellTraceTM Oregon Green R©
488 carboxylic acid diacetate, succinimidyl ester (OG; Life
Technologies), as described previously (20). Each stimulation
condition (media alone, combined CFP-10/ESAT-6 peptide pool,
PPD, and SEB) was set up in duplicate: 10µg/ml LEAFTM purified
anti-human PD-L1 Ab was added to one set of conditions,
and 10µg/ml LEAFTM purified IgG2b isotype-matched control
Ab was added to the duplicate set of conditions. Plates were
incubated for 6 days in a 37◦C incubator with 5% CO2. On
day 6, 50 µl of cell culture supernatants per well were removed
and stored for ELISA analysis (see below). Cells were then
suspended in the remaining supernatant and transferred from the
96-well plate to FACS tubes, where they were re-stimulated with
antigen for 6 h to determine the capacity of proliferating Mtb-
specific CD4T cells to produce Th1 cytokines following cognate
antigen stimulation. Cells were re-stimulated for 6 h on day 6
with the same antigens added on day 0 as follows: 1µg/ml CFP-
10/ESAT-6 peptide pool was added to cells stimulated with CFP-
10/ESAT-6 peptide pool on day 0; 10µg/ml PPD was added to
cells stimulated with PPD on day 0; 1µg/ml SEB was added to
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cells stimulated with SEB on day 0; no antigens were added to
cells in the negative control wells containing media alone. Cells
were incubated at 37◦C for 1 h, then 10µg/ml Brefeldin A was
added, and the cells incubated for an additional 5 h at 37◦C.
Cells were then washed in PBS, stained with Vivid, fixed with
FACS Lysing Solution, permeabilized with Perm/Wash Buffer,
and stained at 4◦C with the following Abs: anti-CD3 APC-H7,
anti-CD4 Qdot605, anti-CD8 PerCP-Cy5.5, anti-PD-1 PE, anti-
IFN-γ Alexa Fluor 700, anti-IL-2 APC, and anti-TNF-α PE-Cy7.
After 1 h, cells were washed with Perm/Wash Buffer, suspended
in PBS, and acquired on a BD LSRII flow cytometer.
IFN-γ ELISA
Cell culture supernatants from each well were harvested on day
6 of the proliferation assay described above. Supernatants were
frozen and stored at−80◦C until use in a DuoSet R© IFN-γ ELISA
(R&D Systems), according to manufacturer’s instructions. The
limit of detection was 16pg/ml of IFN-γ. Data from antigen-
stimulated wells are reported after subtraction of IFN-γ levels in
the negative control wells.
Data Analysis
Flow cytometry data were analyzed using FlowJo version 9.6.4
(Tree Star, Inc.). Compensation was calculated using single-
stained anti-mouse Ig, κ CompBeads (BD Biosciences). Single
cells were gated by plotting forward scatter-area versus forward
scatter-height; lymphocytes were gated based on morphological
characteristics. Viable cells were defined as Vividlo cells;
proliferating cells were defined as OGlo cells. CD4T cells were
defined as CD3+CD4+ lymphocytes; CD8T cells were defined as
CD3+CD8+ lymphocytes.
In whole blood and BAL ICS assays, antigen-specific CD4
and CD8T cell populations were defined as cells producing
cytokines (IFN-γ, TNF-α, and IL-2) after stimulation with
antigen. Responses were considered positive if the frequency
of cytokine-producing CD4 and CD8T cells in the antigen-
stimulated condition met all of the following criteria: (i) the
difference in the absolute number of cytokine+ CD4 or CD8T
cells in the antigen-stimulated versus unstimulated condition
was ≥20 cytokine+ cells, (ii) a minimum frequency of 0.01% of
cytokine+ CD4 or CD8T cells, after subtraction of the frequency
of cytokine+ cells in the negative control, and (iii) a frequency of
cytokine+ CD4 or CD8T cells that was greater than the median
plus 3 times the median absolute deviation of cytokine+ CD4
or CD8T cells in the negative control samples in the cohort.
Phenotypic analysis of PD-1 expression on antigen-specific CD4
and CD8T cells was restricted to individuals who met the above
criteria for a positive response.
In 6-day proliferation assays, proliferative responses were
considered positive if the frequency of proliferating (OGlo) CD4
or CD8T cells in the antigen-stimulated wells met both of the
following criteria: (i) ≥0.01% of OGlo CD4 or CD8T cells, after
subtraction of the frequency of OGlo cells in the negative control
(media alone), and (ii) a frequency of OGlo CD4 or CD8T cells
that was greater than themedian plus 3 times themedian absolute
deviation of OGlo CD4 or CD8T cells in the negative control
samples in the cohort. Analysis of PD-1 expression and cytokine
production by proliferating cells was restricted to individuals
with positive antigen-specific proliferating CD4 and CD8T cell
responses.
Statistical Analysis
Statistical analysis of data was performed using GraphPad
Prism version 7.0b. Differences between three groups were first
evaluated using a non-parametric Kruskal-Wallis test, with p-
values adjusted for multiple comparisons using Dunn’s post-
test. Differences between two groups were evaluated using a
non-parametricMann-Whitney test. Correlations were evaluated
using a non-parametric Spearman rank correlation. Differences
in responses within the same individual measured at two different
time points on TB treatment were evaluated using the Wilcoxon
matched pairs signed rank test. Differences in measurements of
T cell function in the presence or absence of anti-PD-L1 blocking
Ab were evaluated using theWilcoxonmatched pairs signed rank
test. P-values <0.05 were considered significant.
RESULTS
Participants
Participants between the ages of 18–65 years were recruited
in the Western Cape province of South Africa; all participants
were sero-negative for HIV-1 antibodies. Individuals with LTBI
were defined as asymptomatic, healthy adults with no previous
history of TB diagnosis or treatment, and with IFN-γ+ T cell
responses to either CFP-10 and/or ESAT-6 peptide pools. Patients
with newly diagnosed pulmonary TB disease were categorized
into two groups according to sputum smear microscopy results:
smear− TB and smear+ TB. Both groups of TB patients were
older than the LTBI group (Table 1).
TABLE 1 | Characteristics of study population.
Participant group n AFB sputum smear grade Age, years (range)b Sex (% male)
LTBI 48 N/Aa 25 (18–50) 44
Smear− TB 12 Negative 45 (18–59)* 78
Smear+ TB 45 3+ (n = 28); 2+ (n = 6); 1+ (n = 11) 38 (18–65)* 61
aN/A (not applicable).
bValues denote median (range).
*P < 0.05, compared with LTBI.
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PD-1 Expression Is Increased on Subsets
of Naïve and Memory CD4T Cells in
Patients With Smear+ TB
Upregulation of PD-1 expression by CD4 and CD8T cells has
been associated with T cell dysfunction in the setting of chronic
infections, including malaria, HIV, HCV, and HBV (27, 29). We
hypothesized that high bacterial loads in people who develop
active TB disease would result in upregulation of PD-1 expression
on T cells. Using flow cytometry, we measured PD-1 expression
on total CD4 and CD8T cell populations in whole blood from
healthy individuals with LTBI, smear− TB patients, and smear+
TB patients. PD-1 expression was significantly higher on total
CD4T cells in smear+ TB patients, compared with smear−
TB patients and individuals with LTBI (Figure 1A). We next
evaluated PD-1 expression on naïve and memory CD4T cell
subsets, based on CCR7 and CD45RA expression profiles, in
individuals with LTBI and smear+ TB patients (Figure 1B).
As expected, PD-1 expression was highest on effector memory
CD4T cells (TEM; Figure 1C). Compared with individuals with
LTBI, PD-1 expression was significantly higher on naïve (TN),
central memory (TCM), and terminally differentiated effector
memory cells (TEMRA) in patients with smear
+ TB (Figure 1C).
PD-1 expression by CD8T cells was higher in smear+ TB
patients, compared with individuals with LTBI (Figures 1D,E);
however, unlike PD-1 expression on CD4T cells, PD-1
expression was similar between smear− and smear+ TB patients.
Upregulation of PD-1 on total CD8T cells in individuals with
smear+ TB was restricted to the TN CD8T cells (Figure 1F).
Together these data indicate smear+ TB disease is associated with
upregulation of PD-1 expression on multiple subsets of CD4T
cells, with the greatest increase in expression observed by TN
cells.
FIGURE 1 | PD-1 is upregulated on naïve and memory CD4T cell subsets in patients with smear+ TB disease. PD-1 expression was measured by flow cytometry
using whole blood samples obtained from individuals with LTBI (n = 33), and patients with smear− TB (n = 12) and with smear+ TB (n = 29). The MFI of PD-1
expression is shown on the total CD4T cell population (A) and the total CD8T cell population (D). PD-1 expression on naïve and memory CD4 and CD8T cell subsets
was performed on a subset of individuals with LTBI (n = 15) and patients with smear+ TB (n = 15). Representative flow cytometry data are shown of the naïve and
memory T cell profile of CD4T cells (B) and CD8T cells (E) from an individual with LTBI (top row) and a patient with smear+ TB (bottom row). The flow cytometry data
in (B) are gated on viable CD3+CD4+ lymphocytes; the flow cytometry data shown in (E) are gated on viable CD3+CD8+ lymphocytes. TN, TCM, TEM, and TEMRA
subsets are indicated in each quadrant, according to expression of CCR7 and CD45RA. A histogram overlay of PD-1 expression by each T cell subset (TN, TCM,
TEM, and TEMRA ) is shown on the right. Composite data are shown indicating PD-1 MFI on naïve and memory CD4 (C) and CD8T cell subsets (F). Horizontal lines
represent the median. Differences between the three groups in (A, D) were assessed using a Kruskal-Wallis test; the p-values shown have been adjusted for multiple
comparisons using Dunn’s post-test. Differences between two groups in (C, F) were assessed using the Mann-Whitney test. For the box and whiskers plots in (A, D),
the horizontal line represents the median, the boxes the interquartile range, and the whiskers the 10th and 90th percentiles.
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PD-1 Is Upregulated on Mtb-Specific
CD4T Cells in Smear+ TB Patients
We next sought to determine whether PD-1 was differentially
expressed on Mtb-specific CD4T cells in persons with latent
infection and active TB disease. Using a short-term whole blood
intracellular cytokine staining (ICS) assay, PD-1 expression
was measured on CD4T cells producing IFN-γ, TNF-α,
and/or IL-2 following stimulation with immunodominant
Mtb peptide pools (ESAT-6, CFP-10, and TB10.4) and
PPD. PD-1 was upregulated on IFN-γ+ CD4T cells in
smear+ TB patients, compared with smear− TB patients
and individuals with LTBI, for each of the Mtb antigens
tested (Figures 2A–C, Supplementary Figures 1A, B). No
differences in PD-1 expression on Mtb-specific CD4T cells
were found between individuals with LTBI and patients
with smear− TB. PD-1 on IFN-γ+ CD4T cells responding
to HCMV pp65 (Supplementary Figure 1C) and SEB
(Supplementary Figure 1D) was similar between individuals
with LTBI and smear+ TB patients, thus suggesting upregulation
of PD-1 on Mtb-specific CD4T cells may be driven by exposure
to high levels of mycobacterial antigens in vivo.
Varying effector functions have been ascribed to antigen-
specific T cells producing different combinations of cytokines,
with cells producing multiple cytokines simultaneously
considered to have greater functional capacity than T cells
producing a limited number of cytokines (47–49). To determine
whether PD-1 was differentially expressed by functionally
distinct subsets of Mtb-specific CD4T cells, we evaluated PD-1
expression by CD4T cells producing combinations of IFN-γ,
TNF-α, and IL-2 (Figure 2D). Three discrete subsets of ESAT-6-
and TB-10.4-specific CD4T cells were detected, including
polyfunctional IFN-γ+TNF-α+IL-2+ cells, IFN-γ+TNF-
α
+ double-positive cells, and TNF-α+ single-positive cells.
Expression of PD-1 was significantly higher on polyfunctional
and TNF-α+ single-positive subsets of ESAT-6 and TB10.4-
specific CD4T cells in smear+ TB patients, compared with
individuals with LTBI (Figures 2E,F). These findings were
consistent with analysis of PD-1 expression by distinct cytokine+
subsets of PPD-specific CD4T cells, in which PD-1 expression
was significantly higher in smear+ TB patients, compared with
smear− TB and LTBI groups, for each cytokine+ subset detected
(Supplementary Figure 1E). These data indicate that expression
of PD-1 is consistently upregulated on multiple different subsets
of Th1 cytokine+Mtb-specific CD4T cells in patients with newly
diagnosed smear+ TB disease.
PD-1 Expression Is Significantly Lower on
Mtb-Specific CD8 Than CD4T Cells
The identification of PD-1 as a marker of T cell dysfunction
and exhaustion was initially described in the context of virus-
specific CD8T cells (50), and PD-1 expression on virus-specific
CD8T cells has been correlated with antigen load (51). To
determine if PD-1 is upregulated on Mtb-specific CD8T cells
in the setting of chronic Mtb infection, we measured PD-1
expression on cytokine+ CFP-10/ESAT-6-specific CD8T cells in
individuals with LTBI, and in smear− and smear+ TB patients
(Figure 3A). Consistent with previous findings (20, 24, 52, 53),
Mtb-specific cytokine+ CD8T cells were detected less frequently
in individuals with LTBI than patients with active TB disease.
Amongst persons with detectable Mtb-specific, cytokine+ CD8T
cell responses, PD-1 expression was not significantly different
across the three groups (Figure 3B). Similar to CD4T cells,
there was no evidence of upregulation of PD-1 expression
by IFN-γ+ CD8T cells from patients with active TB disease
responding to HCMV pp65 (Supplementary Figure 1F) or SEB
(Supplementary Figure 1G). Moreover, there was no difference
in PD-1 expression by subsets of CFP-10/ESAT-6-specific CD8T
cells producing different combinations of IFN-γ, TNF-α, and
IL-2 (Figure 3C).
The above data indicate PD-1 expression is significantly
upregulated on Mtb-specific CD4T cells, but not Mtb-specific
CD8T cells, in smear+ TB patients with high bacterial loads.
To determine whether PD-1 expression is differentially regulated
between Mtb-specific CD4 and CD8T cells while controlling
for bacterial load, we directly compared PD-1 expression
on CD4 and CD8T cell responses specific for the same
antigen (either CFP-10 or ESAT-6) within the same individual
(Figure 3D). Paired analysis of PD-1 expression on Mtb-specific
CD4 and CD8T cells within the same individual indicated
significantly higher expression of PD-1 on Mtb-specific CD4T
cells, compared with Mtb-specific CD8T cells specific for the
same antigen (Figure 3E). Taken together, these data indicate that
Mtb-specific CD4T cells consistently upregulate PD-1 more than
Mtb-specific CD8T cells.
PD-1 Expression by Mtb-Specific CD4T
Cells Is Similar in BAL and Blood of
Individuals With LTBI
The above data indicating increased PD-1 expression on Mtb-
specific CD4T cells in smear+ TB patients, compared with
healthy, asymptomatic individuals with LTBI, were based on
analysis of Mtb-specific CD4T cells circulating in peripheral
blood, and thus may not reflect the phenotype of Mtb-specific
T cells at the site of infection in the lung. To evaluate PD-
1 expression by T cells in the lung and peripheral blood,
we performed bronchoalveolar lavage (BAL) on a subset of
individuals with LTBI and collected peripheral blood samples
from each individual on the same day as the BAL procedure.
We first compared PD-1 expression on the total CD4 and CD8T
cell populations in paired blood and BAL samples. For both CD4
and CD8T cell populations, expression of PD-1 was significantly
higher on cells isolated from BAL, compared with peripheral
blood from the same individual (Figures 4A,B).
Paired samples of whole blood and BAL were stimulated
with PPD and a combined CFP-10/ESAT-6 peptide pool for
6 h, followed by analysis of PD-1 expression on Th1 cytokine+
antigen-specific CD4T cells. The frequencies of CFP-10/ESAT-
specific CD4T cells were too low for phenotyping in BAL;
however, cytokine+ CD4T cell responses to PPD were present
in BAL at sufficient frequencies for PD-1 phenotypic analysis
in 7 out of 12 individuals. Of these individuals with detectable
cytokine+ CD4T cell responses in both BAL and blood, PD-1
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FIGURE 2 | PD-1 expression on Mtb-specific CD4T cells is increased in patients with smear+ TB, compared with smear− TB patients and individuals with LTBI.
Whole blood from individuals with LTBI (n = 33), and patients with smear− TB (n = 12) and smear+ TB (n = 29), was stimulated for 8 h with an ESAT-6 peptide pool
and a TB10.4 peptide pool; PD-1 expression was measured on total CD4T cells and Ag-specific CD4T cells producing IFN-γ, TNF-α, and/or IL-2. (A) Representative
flow cytometry data indicating PD-1 expression by ESAT-6-specific CD4T cells producing IFN-γ, TNF-α, and/or IL-2. Flow plots are shown gated on viable
CD3+CD4+ lymphocytes; gray cells indicate cytokine− total CD4T cells and black cells indicate cytokine+ (expressing any combination of IFN-γ, TNF-α, and IL-2)
CD4T cells. (B) Composite data of PD-1 expression by IFN-γ+ CD4T cells in individuals with a positive response to ESAT-6 (LTBI: n = 18; smear− TB: n = 9;
smear+ TB: n = 13). (C) Composite data of PD-1 expression by IFN-γ+ CD4T cells in individuals with a positive response to TB10.4 (LTBI: n = 27; smear− TB:
n = 11; smear+ TB: n = 21). (D) Representative flow cytometry data indicating PD-1 expression by the indicated subsets of cytokine-producing CD4T cells following
stimulation with ESAT-6. Dot plots and histograms are shown gated on viable CD3+CD4+ cells. Gray cells indicate cytokine− (IFN-γ− IL-2− TNF-α−) CD4T cells; red
indicates IFN-γ+ IL-2+ TNF-α+ cells; green indicates IFN-γ+ IL-2− TNF-α+ cells; dark blue indicates IFN-γ− IL-2− TNF-α+ cells. Dot plots and histograms of PD-1
expression by ESAT-6-specific cytokine+ CD4T cells are shown from the same donor with either LTBI, smear− TB, and smear+ TB. (E,F) PD-1 expression on
subsets of ESAT-6-specific (E) or TB10.4-specific (F) CD4T cells producing the indicated combinations of IFN-γ, TNF-α, and IL-2. Only cytokine+ subsets present at
≥0.01% of CD4T cells, after subtraction of background cytokine production, were analyzed for PD-1 expression. Differences across three groups were assessed
using a Kruskal-Wallis test; the p-values shown have been adjusted for multiple comparisons using Dunn’s post-test. Horizontal lines in (B,C) represent the median.
For box plots in (E,F), the horizontal line represents the median, the box the interquartile range, and the whiskers the 10th and 90th percentiles.
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FIGURE 3 | PD-1 is expressed at lower levels by CFP-10/ESAT-6-specific CD8T cells, compared with CD4T cells specific for the same antigens. PD-1 expression on
CFP-10 and ESAT-6-specific CD8T cells was performed as described in Figure 2. (A) Representative flow cytometry data indicating PD-1 expression by
CFP-10-specific CD8T cells producing IFN-γ, TNF-α, and/or IL-2. Flow plots are shown gated on viable CD3+CD8+ lymphocytes; gray cells indicate cytokine−
CD8T cells and black cells indicate cytokine-positive CD8T cells expressing any combination of IFN-γ, TNF-α, and IL-2. (B) PD-1 expression by
CFP-10/ESAT-6-specific IFN-γ+ CD8T cells (LTBI: n = 4; smear− TB: n = 4; smear+ TB: n = 13). Differences were assessed by a Kruskal-Wallis test; the p-values
shown have been adjusted for multiple comparisons using Dunn’s post-test. (C) PD-1 expression on subsets of CFP-10/ESAT-6-specific CD8T cells from smear+ TB
patients producing the indicated combinations of IFN-γ, TNF-α, and IL-2. Only cytokine+ subsets present at ≥ 0.01% of CD8T cells, after subtraction of background
cytokine production, were analyzed for PD-1 expression. No significant differences in PD-1 expression were found between any of the different cytokine-producing
subsets (Kruskal-Wallis test). (D) Histogram overlay comparison of PD-1 expression on IFN-γ+ CD4 and CD8T cells following stimulation of whole blood from a
smear+ TB patient with a CFP-10 peptide pool. The dotted line represents PD-1 MFI on IFN-γ+ CD4T cells and the solid line represents PD-1 MFI on IFN-γ+ CD8T
cells measured at the same time in the same individual. (E) Comparison of PD-1 expression on IFN-γ+ CD4 and CD8T cells specific for the same antigen (either a
CFP-10 peptide pool or an ESAT-6 peptide pool) within the same individual (n = 9 smear+ TB patients). Differences in PD-1 expression between Mtb-specific CD4
and CD8T cell responses within the same individual were determined by the Wilcoxon matched pairs signed rank test. For box plots in (B, C), the horizontal line
represents the median, the box the interquartile range, and the whiskers the 10th and 90th percentiles.
expression was not significantly different on PPD-specific CD4T
cells in the two compartments (Figures 4C,D). We were unable
to detect sufficient frequencies of cytokine+ CD8T cells in BAL
samples to evaluate PD-1 expression on Mtb-specific CD8T cells
in BAL and blood (data not shown).
PD-1 Expression on Mtb-Specific CD4T
Cells Decreases in Smear+ TB Patients
After Treatment
We observed increased levels of PD-1 expression by Mtb-
specific CD4T cells in patients with smear+ TB disease, but
not in patients with smear− TB disease, thus suggesting PD-
1 expression on CD4T cells may reflect bacterial load and
thus relate to the level of mycobacterial antigen exposure.
To directly assess whether PD-1 expression on Mtb-specific
CD4T cells is associated with bacterial load, we measured
PD-1 expression longitudinally on CFP-10 and ESAT-6-specific
CD4T cells on a subset of smear+ TB patients during TB
treatment. By the end of the 6-month TB treatment period, PD-
1 expression on IFN-γ+ CD4T cells had significantly decreased,
compared with pre-treatment levels (Figures 5A,B). By contrast,
no significant differences were observed in PD-1 expression by
CFP-10 and ESAT-6-specific, IFN-γ+ CD8T cells in smear+
TB patients after completion of treatment (Figures 5D,E). PD-
1 expression on the total CD4 and CD8T cell populations
did not significantly change following completion of anti-TB
treatment (Figures 5C,F). Taken together, these data provide
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FIGURE 4 | PD-1 expression by PPD-specific CD4T cells is similar in the lung and peripheral blood of individuals with LTBI. Bronchoalveolar lavage (BAL) was
performed on individuals with LTBI (n = 12); blood samples collected just prior to the BAL procedure. Whole blood and cells isolated from BAL fluid were stimulated in
parallel with PPD for 6 h. PD-1 expression was measured on cytokine+ (IFN-γ, TNF-α, and/or IL-2) PPD-specific and total CD4 and CD8T cells in blood and BAL by
flow cytometry. (A) Flow cytometry data of PD-1 expression by T cells from paired blood and BAL samples from a single individual with LTBI. Plots are shown gated
on viable CD3+ T lymphocytes. (B) Comparison of PD-1 expression on the total CD4 and CD8T cell populations in paired blood and BAL samples from individuals
with LTBI. (C) Flow cytometry data indicating PD-1 expression by cytokine+, PPD-specific CD4T cells from paired blood and BAL samples from two individuals with
LTBI. Plots are shown gated on viable CD3+CD4+ lymphocytes. Cells in gray indicate cytokine− CD4T cells (for both blood and BAL samples); cells in red indicate
PPD-specific CD4T cells in the blood producing any combination of IFN-γ, TNF-α, and IL-2; cells in blue indicate PPD-specific CD4T cells in BAL producing any
combination of IFN-γ, TNF-α, and IL-2. (D) Comparison of PD-1 expression by PPD-specific CD4T cells producing any combination of IFN-γ, TNF-α, and IL-2 in
paired blood and BAL samples from individuals with LTBI (n = 7). Differences in (B, D) were assessed using the Wilcoxon matched pairs signed rank test.
further evidence that high bacterial loads in patients with smear+
TB disease drive increased expression of PD-1 on Mtb-specific
CD4T cells, and that PD-1 expression decreases on Mtb-specific
CD4T cells following successful treatment of pulmonary TB.
Blockade of PD-1/PD-L1 Signaling in vitro
Augments Mtb-Specific IFN-γ Production
Numerous studies in chronic viral infections have indicated
virus-specific CD4 and CD8T cell function, including cytokine
production and proliferation, can be augmented or restored
following blockade of the PD-1 signaling pathway, either in
animal studies in vivo (50, 54, 55), or in human studies in vitro
(51, 56, 57). We have previously reported that Mtb-specific T
cell proliferative capacity is impaired in patients with active TB
disease (20, 24). To determine whether blockade of the PD-
1/PD-L1 signaling pathway in vitro could restore or augment the
proliferative capacity of Mtb-specific CD4T cells in patients with
smear+ TB, PBMC were labeled with the cytosolic dye Oregon
Green (OG) and cultured for 6 days with Mtb antigens in the
presence of an anti-PD-L1 blocking Ab or an isotype-matched
control Ab (Figure 6A). Blockade of the PD-1/PD-L1 pathway
enhanced CD4T cell viability in PBMC cultured for 6 days with
media alone, although this difference was abrogated when cells
were stimulated with Mtb antigens (Supplementary Figure 2).
No differences in the proliferative capacity of Mtb-specific CD4T
were found in the presence of anti-PD-L1 blocking Ab, compared
with an isotype control Ab, for either the LTBI (Figure 6B) or
smear+ TB groups (Figure 6C). Together these data indicate
that in vitro blockade of the PD-1/PD-L1 signaling pathway may
promote CD4T cell survival but is not sufficient to overcome the
dysfunction in proliferative capacity of Mtb-specific CD4T cells
in patients with smear+ TB disease.
We next evaluated the capacity of PD-1/PD-L1 blockade to
augment cytokine production by Mtb-specific T cells. Using an
ELISA for measurement of IFN-γ in cell culture supernatants
collected on day 6 of the proliferation assay, we found that PD-
1/PD-L1 blockade enhanced PPD-induced IFN-γ production in
both LTBI and smear+ TB groups (Figures 6D,E). However,
PD-1/PD-L1 blockade did not significantly augment IFN-γ
production to CFP-10/ESAT-6 peptide pool stimulation in either
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FIGURE 5 | PD-1 expression on Mtb-specific CD4T cells is associated with bacterial load. Flow cytometry was used to measure PD-1 expression on
CFP-10/ESAT-6-specific IFN-γ+ CD4 and CD8T cells in smear+ TB patients at 3 time points: prior to initiation of TB treatment (pre-TB Tx), and 2 and 6 months
following initiation of treatment. (A) Histogram overlay of PD-1 expression on IFN-γ+ CD4T cells following 8 h stimulation of whole blood from a smear+ TB patient
with a CFP-10 peptide pool at the three time points indicated. PD-1 MFI is shown after gating on viable CD3+CD4+ IFN-γ+ lymphocytes. (B) Longitudinal analysis of
PD-1 expression on CFP-10/ESAT-6-specific IFN-γ+ CD4T cells within the same individuals over time (n = 6 smear+ TB patients with IFN-γ+ CD4T cell responses
detectable at more than one time point). (C) Median and interquartile range of PD-1 expression on total CD4T cells from the same smear+ TB patients shown in (B).
(D) Histogram overlay of PD-1 expression by IFN-γ+ CD8T cells following 8 h stimulation of whole blood from a smear+ TB patient with a CFP-10 peptide pool at the
three time points indicated. PD-1 MFI is shown after gating on viable CD3+CD8+ IFN-γ+ lymphocytes. (E) Longitudinal analysis of PD-1 expression on
CFP-10/ESAT-6-specific IFN-γ+ CD8T cells within the same individual over time (n = 4 smear+ TB patients with IFN-γ+ CD8T cell responses detectable at more
than one time point). (F) Median and interquartile range of PD-1 expression on total CD8T cells from the same smear+ TB patients shown in (E). For (B,C,E,F),
differences in PD-1 expression prior to (pre-TB Tx) and at the end of TB treatment (6 mo. TB Tx) were determined using the Wilcoxon matched pairs signed rank test.
group. These data indicate the capacity of PD-1/PD-L1 blockade
to enhance Mtb-specific IFN-γ production is not dependent on
Mtb infection status.
Expression of PD-1 Is Induced on
Proliferating Mtb-Specific T Cells
Following in vitro Culture With Mtb
Antigens
The above data suggest that PD-1/PD-L1 blockade can increase
Mtb-specific IFN-γ production in both groups of individuals
with LTBI and active TB, but does not augment Mtb-specific
T cell proliferative capacity in smear+ TB patients. To further
evaluate the relationship between PD-1 expression and Mtb-
specific T cell proliferative capacity, wemeasured PD-1 on CD4T
cells in whole blood directly ex vivo, and on PBMC cultured for 6
days with media alone, CFP-10/ESAT-6 peptide pool, and SEB
(Figure 7A). In the absence of exogenous antigen stimulation,
PD-1 expression decreased significantly on CD4T cells in PBMC
cultured in media alone, compared with PD-1 expression on
CD4T cells circulating in peripheral blood ex vivo (Figure 7B).
In both LTBI and smear+ TB groups, incubation of PBMC for
6 days with CFP-10/ESAT-6 peptides induced expression of PD-
1 at significantly higher levels than PBMC cultured in media
alone (Figures 7B,C). However, stimulation with CFP-10/ESAT-
6 peptides induced PD-1 expression on a significantly greater
percentage of CD4T cells in individuals with LTBI, compared
with smear+ TB patients (Figure 7D). The differential induction
of PD-1 expression by CD4T cells in LTBI and smear+ TB was
particular to Mtb antigen stimulation, as indicated by the similar
levels of PD-1 expression induced by CD4T cells in the two
groups following mitogenic stimulation with SEB (Figure 7D).
We next determined whether PD-1 was differentially
expressed by proliferating (OGlo) and non-proliferating CD4T
cells (Figure 7E). The majority of CD4T cells that proliferated
to CFP-10/ESAT-6 peptides also expressed PD-1, both in
individuals with LTBI and in smear+ TB patients (Figure 7E).
Moreover, a significant and strong positive correlation was found
between the frequencies of proliferating CD4T cells and PD-1+
CD4T cells in CFP-10/ESAT-6-stimulated PBMC cultures
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FIGURE 6 | Blockade of the PD-1/PD-L1 signaling pathway can augment Mtb-specific IFN-γ secretion, but not CD4T cell proliferative capacity. Proliferation assays
were performed using freshly isolated PBMC labeled with Oregon Green (OG) and incubated for 6 days under the following conditions: media alone (negative control),
CFP-10/ESAT-6 peptide pool, and SEB (positive control). Proliferation assays were performed in the presence of either anti-PD-L1 blocking Ab, or an IgG2b
isotype-matched control Ab (n = 13 LTBI; n = 13 smear+ TB). (A) Flow cytometry data indicating the frequency of proliferating CD4T cells following stimulation with
CFP-10/ESAT-6 peptide pool, in the presence of anti-PD-L1 Ab or IgG2b isotype control Ab. Dot plots are shown gated on viable CD3+CD4+ lymphocytes from an
individual with LTBI (left) and a patient with smear+ TB (right). (B,C) Comparison of the frequency of proliferating (OGlo) CD4T cells stimulated with CFP-10/ESAT-6
peptide pool, in the presence of anti-PD-L1 Ab or IgG2b isotype control Ab. (D,E) Levels of IFN-γ in cell culture supernatants of PBMC stimulated with
CFP-10/ESAT-6 peptide pool for 6 days in the presence of anti-PD-L1 Ab or IgG2b isotype control Ab. Levels of IFN-γ were quantified by ELISA; data are shown after
subtraction of background IFN-γ production in the negative control (media alone) conditions. Differences in proliferative capacity and IFN-γ secretion in the presence
and absence of anti-PD-L1 Ab were determined using the Wilcoxon matched pairs signed rank test.
(Figure 7F). Taken together, these data suggest that exposure to
Mtb antigens in vitro induces expression of PD-1 on proliferating
Mtb-specific CD4T cells. By contrast with Mtb-induced PD-1
expression on CD4T cells, PD-1 expression was relatively low on
CD8T cells cultured for 6 days with CFP-10/ESAT-6 peptide pool
and did not differ between individuals with LTBI and smear+
TB, with the majority of proliferating CFP-10/ESAT-6-specific
CD8T cells lacking PD-1 expression (data not shown). These
data provide further evidence of differential regulation of PD-1
expression on Mtb-specific CD4 and CD8T cells.
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FIGURE 7 | PD-1 expression is induced on CFP-10/ESAT-6-specific CD4T cells proliferating in vitro. Proliferation assays performed as described in Figure 6. PD-1
expression was measured by flow cytometry on total CD4T cells and CFP-10/ESAT-6-specific proliferating (OGlo) CD4T cells on day 6 of culture. (A) Flow cytometry
data indicating PD-1 expression on total CD4T cells in whole blood directly ex vivo (Day 0, ex vivo), and PD-1 expression on total CD4T cells after incubation for 6
days in the absence of exogenous Ag stimulation (Day 6, media control), and after stimulation with CFP-10/ESAT-6 peptide pool for 6 days (Day 6, CFP-10/ESAT-6
peptide pool). Flow plots are shown gated on viable CD3+CD4+ lymphocytes. The percentages of PD-1+ CD4T cells are shown in each plot. Each of the three flow
plots shown are from a single individual (top row: LTBI; bottom row: smear+ TB). (B,C) Composite data indicating the percentage of PD-1+ CD4T cells in each
indicated condition for individuals with LTBI [(B), n = 28] and patients with smear+ TB [(C), n = 23]. Differences between PD-1 expression by CD4T cells in each
condition were determined by the Wilcoxon matched pairs rank sum test. (D) Comparison of the frequency of PD-1+ CD4T cells in individuals with LTBI and smear+
TB patients following stimulation with CFP-10/ESAT-6 peptide pool and SEB. Horizontal lines represent the median. Differences between the two groups were
determined using a Mann-Whitney test. (E) Flow cytometry data indicating expression of PD-1 by proliferating (OGlo) CFP-10/ESAT-6-specific CD4T cells. Flow plots
are shown gated on viable CD3+CD4+ lymphocytes; data are shown from an individual with LTBI (top row) and a patient with smear+ TB (bottom row). (F)
Correlation between the frequency of proliferating (OGlo) CD4T cells and the frequency of PD-1+ CD4T cells in individuals with LTBI (open circles) and smear+ TB
patients (gray circles), following stimulation of PBMC with CFP-10/ESAT-6 peptide pools. Significance was determined using the Spearman rank correlation.
Mtb-Specific CD4T Cells That Proliferate
Also Upregulate PD-1 and Maintain Robust
Th1 Antigen-Specific Cytokine Production
Capacity
We next examined the functional capacity of Mtb-specific
CD4T cells that upregulated expression of PD-1 during the
6-day in vitro culture with Mtb peptide pools. To determine
whether induction of PD-1 expression in vitro was associated
with evidence of Mtb-specific CD4T cell dysfunction, OG-
labeled PBMC were re-stimulated with CFP-10/ESAT-6 peptides
for the final 6 h of the 6-day culture. Cells were analyzed
by flow cytometry to measure proliferation, PD-1 expression,
and intracellular IFN-γ and TNF-α expression. Proliferating
Mtb-specific CD4T cells retained the capacity to produce Th1
cytokines upon antigen re-stimulation on day 6 of culture
(Figure 8A). Interestingly, the majority of IFN-γ+ proliferating
CD4T cells were also PD-1+ (Figure 8B).
To determine whether PD-1+ versus PD-1− proliferating
CD4T cells exhibit differential cytokine production capacity,
cells were first gated on Mtb-specific proliferating cells
(OGloCD4+), then gated on PD-1+ and PD-1− populations
and evaluated for intracellular IFN-γ and TNF-α production
(Figures 8C,D). In both groups of individuals with LTBI and
smear+ TB, Mtb-specific proliferating CD4T cells that expressed
PD-1 maintained significantly greater cytokine production
capacity than PD-1− CD4T cells (Figure 8E). Together these
data indicate that in vitro culture with Mtb antigens induces PD-
1 expression by the majority of proliferating Mtb-specific CD4T
cells, and that PD-1+ proliferating CD4T cells retain robust
capacity to produce Th1 effector cytokines.
DISCUSSION
Sustained high expression of PD-1 has been associated with T
cell dysfunction in chronic viral infections and tumors (29, 30).
Active pulmonary TB disease is characterized by high bacterial
loads in the lung, yet the relationship between bacterial load,
PD-1 expression, and Mtb-specific T cell function in human
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FIGURE 8 | PD-1+ proliferating Mtb-specific CD4T cells exhibit greater antigen-specific cytokine production capacity than PD-1− proliferating cells. PBMC
proliferation assays were performed as described in Figure 6. On day 6 of the assay, cells were re-stimulated with a CFP-10/ESAT-6 peptide pool for 6 h, and then
analyzed by flow cytometry for expression of PD-1 and intracellular IFN-γ and TNF-α. (A) Flow cytometry data indicating IFN-γ production capacity by proliferating
CD4T cells following incubation of OG-labeled PBMC for 6 days in medium alone, or with a CFP-10/ESAT-6 peptide pool. Cells were re-stimulated with the same
peptide pool for 6 h on day 6 to measure cytokine production capacity. Plots are shown gated on viable CD3+CD4+ lymphocytes; data are shown from an individual
with LTBI (top row) and a patient with smear+ TB (bottom row). (B) Flow cytometry data indicating co-expression of PD-1 and IFN-γ by OGlo CD4T cells following
stimulation with a CFP-10/ESAT-6 peptide pool. Plots are shown gated on viable CD3+CD4+ lymphocytes; data are shown from an individual with LTBI (top row) and
a patient with smear+ TB (bottom row). Gray cells indicate total CD4T cells; black cells indicate IFN-γ+ CD4T cells. (C,D) Flow cytometry data indicating the gating
strategy for analysis of cytokine production capacity by PD-1− and PD-1+ proliferating CFP-10/ESAT-6-specific CD4T cells. Cells were first gated on viable
CD3+CD4+ lymphocytes, then on proliferating (OGlo) CD4T cells, which were then gated on PD-1− and PD-1+ cells, and further analyzed for intracellular IFN-γ and
TNF-α production. Data shown in (C) are from an individual with LTBI; data shown in (D) are from a patient with smear+ TB. (E) Proportion of CFP-10/ESAT-6-specific
PD-1− and PD-1+ proliferating CD4T cells that produce IFN-γ and/or TNF-α following re-stimulation with CFP-10/ESAT-6 peptide pools for the final 6 h of the 6-day
proliferation assay. Only individuals with CFP-10/ESAT-6-specific CD4T cell proliferation above background were included in this analysis (n = 28 LTBI; n = 18
smear+ TB). Horizontal lines represent the median. Differences between cytokine production capacity of PD-1− and PD-1+ proliferating CD4T cells was determined
using the Wilcoxon matched pairs signed rank test.
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TB has not been well-defined. Using well-characterized cohorts
of adults in South Africa with LTBI and with newly-diagnosed
smear− and smear+ pulmonary TB disease, we have made the
following key findings: (i) PD-1 expression is upregulated on
total CD4T cells and multiple different Th1 cytokine-producing
subsets of Mtb-specific CD4T cells in patients with smear+
TB, compared with smear− TB patients and asymptomatic
individuals with LTBI; (ii) PD-1 expression on Mtb-specific
CD4T cells decreases in patients with smear+ TB following
completion of anti-TB treatment; (iii) in vitro blockade of the
PD-1/PD-L1 signaling pathway enhances Mtb-specific IFN-γ
production, but is insufficient to restore robust Mtb-specific
CD4T cell proliferative capacity in patients with smear+ TB; and
(iv) in vitro culture of PBMC with Mtb antigens induces PD-1
expression on Mtb-specific CD4T cells that proliferate and have
robust Th1 cytokine production capacity.
Our observations that PD-1 is upregulated on Mtb-specific
CD4T cells in smear+ TB patients are consistent with previous
studies of human chronic viral infections, which indicate that
PD-1 is upregulated on virus-specific T cells and correlates
with viral load (51, 58–62). Our data are also consistent with a
previous study in mice reporting that PD-1 is expressed at high
levels on ESAT-6-specific CD4T cells following Mtb infection
(34). Interestingly, PD-1 was significantly upregulated on Mtb-
specific CD4T cells from patients with smear+ but not smear−
TB disease, suggesting that bacterial load in particular drives
increased PD-1, and that the inflammatory milieu of pulmonary
TB disease alone is insufficient to significantly increase PD-
1 expression. The smear+ TB patients in our cohort were
older than in our LTBI cohort (Table 1) and we found a weak
positive correlation between age and PD-1 expression on total
CD4T cells (p = 0.04, r = 0.24; data not shown); however,
we found no significant correlation between age and PD-1
expression onMtb-specific CD4 or CD8T cells (data not shown).
Further evidence that PD-1 on Mtb-specific CD4T cells is
driven by bacterial load is provided by our longitudinal studies
indicating that expression of PD-1 on Mtb-specific CD4T cells
from patients with smear+ TB disease is significantly reduced
following successful completion of anti-TB treatment. PD-1
expression on the total CD4T cell population in this subset of
TB patients did not change significantly over time with anti-TB
treatment, thus indicating that upregulation of PD-1 on Mtb-
specific CD4T cells from smear+ TB patients is driven by cognate
antigen recognition. These results are consistent with a previous
study reporting that concomitant antiretroviral therapy and TB
treatment in HIV-infected TB patients resulted in a reduction
of PD-1 expression on PPD-specific CD4T cells (63). Additional
longitudinal studies of larger cohorts of HIV-uninfected patients
with active TB disease are required to closely monitor PD-1
expression on Mtb-specific CD4T cells to evaluate the utility of
PD-1 as a biomarker for treatment response, and as a potential
predictor of relapse of reinfection.
By contrast with human viral infections in which upregulation
of PD-1 has been widely reported on virus-specific CD8T cells,
we found that expression of PD-1 on Mtb-specific CD8T cells
is similar across individuals with LTBI, smear− TB and smear+
TB, consistent with a previous report that expression of PD-1
on Mtb-specific CD8T cells is not significantly different between
individuals with LTBI and active TB disease (53). By directly
comparing PD-1 expression on Mtb-specific CD4 and CD8T
cells within the same individual, we were able to demonstrate
significantly higher PD-1 expression on CD4T cells, compared
with CD8T cells specific for the same Mtb antigen within the
same individual. The lower level of PD-1 expression on Mtb-
specific CD8T cells, compared with CD4T cells, may reflect
lower levels of Mtb antigen presentation by MHC class I
molecules, relative to MHC class II molecules in Mtb-infected
cells, and potentially differential recognition of Mtb-infected
macrophages between antigen-specific CD4 and CD8T cells, as
indicated by recent studies in mice (64). Taken together, these
provide further evidence that CD4 and CD8T cell responses are
differentially generated and regulated in Mtb infection.
While our data support the conclusion that PD-1 expression
on Mtb-specific CD4T cells is driven by bacterial load, it is
important to note that these data were generated by analysis
of Mtb-specific CD4T cells circulating in peripheral blood.
Given that Mtb infects alveolar macrophages in the lung, we
hypothesized that higher Mtb antigen exposure in the lung may
promote higher expression of PD-1 on Mtb-specific CD4T cells
in the lung than in peripheral blood. Consistent with previous
reports of PD-1 expression on T cells in paired BAL and blood
samples (65, 66), PD-1 was expressed at higher levels on total
CD4 and CD8T cells in BAL from individuals with LTBI,
compared with peripheral blood. Importantly, we demonstrate
that PD-1 expression on Mtb-specific CD4T cells in BAL is
similar to that observed on Mtb-specific CD4T cells circulating
in peripheral blood. Unfortunately, due to infection control
precautions, we were unable to conduct BAL on patients with
smear+ TB within the first 7 days of anti-TB treatment, our
defined cutoff period of sample collection from patients with
active TB disease. Nevertheless, our findings of similar levels
of PD-1 expression on Mtb-specific CD4T cells in BAL and
blood provide an important novel insight into PD-1 expression
in human Mtb infection and further validate our findings in
peripheral blood that PD-1 expression is differentially expressed
onMtb-specific CD4T cells in individuals with LTBI and patients
with smear+ TB disease.
The discovery that immunoregulatory molecules such as PD-
1 and CTLA-4 are amenable to therapeutic manipulation by
antibodies that block these signaling pathways has revolutionized
cancer immunotherapy (67–71), and is a potential avenue for
novel approaches in the treatment of infectious diseases (29). The
potential for PD-1 blockade to improve disease outcomes was
the rationale for previous studies of Mtb infection in PD-1−/−
mice. Surprisingly, mice that lack PD-1 are exceptionally sensitive
to TB, with increased bacterial loads, exacerbated pathology
and decreased survival, compared with wild-type mice (34–36).
These important studies in mice provide compelling evidence
that inhibition of T cells by PD-1 is necessary to prevent excess
IFN-γ production and detrimental immune-mediated pathology.
Consistent with the in vivo studies of Mtb-infected PD-1−/−
mice, our in vitro studies indicated that PPD-specific IFN-γ
production is increased following blockade of the PD-1/PD-L1
signaling pathway. Increased PPD-induced IFN-γ production
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was observed in both LTBI and smear+ TB groups, suggesting
that the capacity of PD-1/PD-L1 blockade to augment Mtb-
specific IFN-γ production is not unique to Mtb infection status
and is not directly correlated with ex vivo expression of PD-
1, which was significantly lower on PPD-specific CD4T cells in
individuals with LTBI, compared with smear+ TB. Alternatively,
the capacity of PD-1/PD-L1 blockade to modulate Mtb-specific
functional capacity could be more directly related to surface
expression of PD-L1, which we did not evaluate in our cohort.
Additionally, since we measured IFN-γ alone as a readout
of Mtb-specific cytokine production, we cannot preclude the
possibility that other cytokines or T cell effector functions, such
as cytotoxicity, are differentially modulated in LTBI and smear+
TB patients following PD-1/PD-L1 blockade.
Our experimental approach to in vitro blockade of the
PD-1/PD-L1 pathway utilized anti-PD-L1 antibodies, as we
and others have previously used in in vitro studies of PD-1
signaling in chronic human viral infections (51, 58–60, 62, 72).
A small number of previous studies have conducted in vitro
blockade of PD-1/PD-L1 in PBMC from TB patients, which
have utilized either anti-PD-1 antibodies or a combination of
anti-PD-L1 and anti-PD-L2 antibodies (40, 41, 73). While one
study reported that blockade of PD-1/PD-L1 signaling during
a short-term 6 h stimulation with Mtb did not significantly
enhance Mtb-specific IFN-γ production (40), our results are
consistent with two previous studies of stimulation of PBMC
with Mtb antigens in the presence of PD-1/PD-L1 blockade
for ≥3 days (41, 73), which demonstrate Mtb-specific IFN-
γ production can be enhanced by blocking PD-1 signaling
pathway. Taken together, these in vitro studies of in vitro PD-
1/PD-L1 blockade using PBMC from TB patients are consistent
with increased IFN-γ production observed in Mtb-infected
PD-1−/− mice (34, 35). Given the exacerbated pathology and
increased mortality in Mtb-infected PD-1-deficient mice, it is
plausible that enhancing Mtb-specific T cell IFN-γ production
by PD-1 blockade in Mtb-infected individuals could ultimately
have detrimental effects, as suggested by recent case reports of
reactivation of TB in cancer patients treated with anti-PD-1
immunotherapy (74–76).
Despite an increase in Mtb-specific IFN-γ production in
both LTBI and smear+ TB groups, we did not observe any
significant enhancement of Mtb-specific CD4T cell proliferative
capacity with PD-1/PD-L1 blockade, a function that we and
other have previously reported to be impaired in patients with
smear+ TB (20, 24, 77). By conducting in-depth analysis of PD-
1 expression profiles in our proliferation assays, we determined
that expression of PD-1 is significantly downregulated, compared
with ex vivo expression, on resting CD4T cells cultured for
6 days in the absence of exogenous antigen stimulation. By
contrast, PD-1 expression is induced at high levels on Mtb-
specific CD4T cells that have proliferated in response to 6-day
Mtb antigen stimulation. These data provide additional support
for the notion that PD-1 expression is indicative of recently
activated Mtb-specific effector CD4T cells, and are consistent
with transient upregulation of PD-1 on antigen-specific T cells
described in acute infections (78). Our in vitro findings of Mtb
antigen-induced PD-1 expression further corroborate our ex vivo
findings that PD-1 is significantly upregulated on Mtb-specific
CD4T cells in the setting of high bacterial load in smear+
TB, indicating recent Mtb antigen exposure in vivo, compared
with LTBI individuals who have either cleared Mtb or maintain
bacterial loads below the level of detection by sputum culture.
Regarding the functional capacity of CD4T cells that express
PD-1, our in vitro studies clearly demonstrated that cytokine
production capacity is preferentially contained within the subset
of proliferating Mtb-specific CD4T cells that express PD-1,
compared with proliferating cells that lack PD-1 expression.
These data are also consistent with our ex vivo observations
that PD-1+ Mtb-specific CD4T cells possess polyfunctional
cytokine production capacity (Figure 2). These findings are in
line with a recent report that a subset of PD-1hi CD4T cells
have greater cytokine production capacity than PD-1low CD4T
cells in healthy individuals (79), and a report that PD-1+ CD4T
cells in HIV-infected children preferentially maintain robust
Th1 and Th17 cytokine production, compared with PD-1−
CD4T cells (80). Our findings thus support a growing body
of evidence that PD-1 expression alone does not necessarily
identify antigen-specific CD4T cells with impaired functional
capacity.
It is important to note that Mtb-specific CD4T cells from
patients with smear+ TB disease had higher PD-1 expression
ex vivo and reduced proliferative capacity in vitro, compared
with individuals with LTBI, yet Mtb-specific CD4T cells from
smear+ TB that had proliferated also expressed PD-1 (Figure 8).
Our data indicate that the majority of proliferating Mtb-specific
CD4T cells express PD-1 on day 6 of our proliferation assays, in
both LTBI and smear+ TB patients; however, it remains unclear
whether the proliferating Mtb-specific CD4T cell population
originates from cells that expressed PD-1 ex vivo, or whether
Mtb-specific CD4T cells with proliferative capacity induced
PD-1 expression only transiently during the 6-day antigen
stimulation period. Our data from individuals with LTBI, who
express low levels of PD-1 on Mtb-specific CD4T cells ex vivo,
strongly indicate that PD-1 is induced on proliferating cells
during 6-day antigen stimulation. Future studies in which PBMC
are first sorted into PD-1+ and PD-1− populations prior to
incubation with Mtb antigens in proliferation assays would be
necessary to definitely determine whether proliferative capacity
is preferentially maintained within PD-1+ and PD-1− CD4T cell
populations.
In summary, we have conducted a detailed study of PD-1
expression profiles and effector functions on Mtb-specific CD4
and CD8T cells in individuals with LTBI and active TB disease.
Overall, our data indicate that expression of PD-1 on Mtb-
specific CD4T cells, but not CD8T cells, defines a population
of effector cells with Th1 cytokine production capacity that have
recently encountered cognate antigen. These studies provide
novel insights into the role of the PD-1 pathway in regulating
T cell responses in Mtb infection and provide a platform for
future studies to determine the utility of PD-1 expression on
antigen-specific CD4T cells as a biomarker for bacterial load and
treatment response in human TB.
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